Dr. Reddy's Laboratories Ltd. (RDY)
12.34
+0.12
(+0.98%)
USD |
NYSE |
Aug 25, 16:00
12.34
0.00 (0.00%)
Pre-Market: 19:59
Dr. Reddy's Laboratories Enterprise Value : 10.21B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 10.21B |
| August 24, 2026 | 10.11B |
| August 21, 2026 | 10.08B |
| August 20, 2026 | 10.02B |
| August 19, 2026 | 10.02B |
| August 18, 2026 | 10.06B |
| August 17, 2026 | 10.02B |
| August 14, 2026 | 10.16B |
| August 13, 2026 | 10.28B |
| August 12, 2026 | 10.26B |
| August 11, 2026 | 10.31B |
| August 10, 2026 | 10.06B |
| August 07, 2026 | 10.11B |
| August 06, 2026 | 10.02B |
| August 05, 2026 | 10.05B |
| August 04, 2026 | 10.01B |
| August 03, 2026 | 9.989B |
| July 31, 2026 | 9.806B |
| July 30, 2026 | 9.789B |
| July 29, 2026 | 9.731B |
| July 28, 2026 | 9.706B |
| July 27, 2026 | 9.739B |
| July 24, 2026 | 9.756B |
| July 23, 2026 | 9.764B |
| July 22, 2026 | 9.414B |
| Date | Value |
|---|---|
| July 21, 2026 | 10.40B |
| July 20, 2026 | 10.37B |
| July 17, 2026 | 10.43B |
| July 16, 2026 | 10.51B |
| July 15, 2026 | 10.57B |
| July 14, 2026 | 10.63B |
| July 13, 2026 | 10.70B |
| July 10, 2026 | 10.92B |
| July 09, 2026 | 11.50B |
| July 08, 2026 | 11.70B |
| July 07, 2026 | 12.12B |
| July 06, 2026 | 11.90B |
| July 02, 2026 | 11.91B |
| July 01, 2026 | 11.59B |
| June 30, 2026 | 12.00B |
| June 29, 2026 | 12.33B |
| June 26, 2026 | 12.76B |
| June 25, 2026 | 12.65B |
| June 24, 2026 | 12.16B |
| June 23, 2026 | 11.87B |
| June 22, 2026 | 11.53B |
| June 18, 2026 | 11.02B |
| June 17, 2026 | 10.90B |
| June 16, 2026 | 11.03B |
| June 15, 2026 | 11.05B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 85.56B |
| Teva Pharmaceutical Industries Ltd. | 57.61B |
| Novo Nordisk A/S | 177.36B |
| Perrigo Co. Plc | 5.067B |
| Innoviva, Inc. | 1.228B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 45.92M |
| Revenue (Quarterly) | 852.30M |
| Total Expenses (Quarterly) | 805.46M |
| EPS Diluted (Quarterly) | 0.0562 |
| Gross Profit Margin (Quarterly) | 42.70% |
| Profit Margin (Quarterly) | 5.39% |
| Earnings Yield | 3.61% |
| Operating Earnings Yield | 3.58% |